Dr. Vidal on Choosing Between Available Trastuzumab Biosimilars

Video

In Partnership With:

Gregory Vidal, MD, PhD, discusses how the field will determine which trastuzumab (Herceptin) biosimilar to prescribe in clinical practice.

Gregory Vidal, MD, PhD, assistant professor, Department of Hematology/Oncology, The University of Tennessee Health Science Center, and medical oncologist, West Cancer Center, discusses how the field will determine which trastuzumab (Herceptin) biosimilar to prescribe in clinical practice.

Five trastuzumab biosimilars have received regulatory approval from the FDA. Once the patent for trastuzumab expires, these agents can be used in clinical practice. Although biosimilars can be marketed at a lower cost than biologic therapy, biosimilars themselves confer no advantage over one another, says Vidal.

As such, the decision of which biosimilar to prescribe may depend on the patients’ insurance, adds Vidal. Vidal anticipates that in the future, insurance providers will work with pharmacy benefit managers to determine which biosimilar to cover.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,